Post-Translational Modification (PTM) Prediction

Platforms scan primary amino acid sequences for known linear motifs susceptible to enzymatic or chemical modification. Deamidation is predicted at Asn-Gly (NG) and Asn-Ser (NS) motifs, while oxidation is forecast for solvent-exposed Methionine (Met) and Tryptophan (Trp) residues. Glycation sites are identified at lysine residues in flexible loops. These models are trained on mass spectrometry-derived datasets that map experimentally verified modification sites, enabling rapid screening of thousands of antibody variants in early discovery.

• Detects canonical motifs: NG, NS, NN for deamidation
• Flags Met and Trp for oxidation susceptibility
• Screens lysine residues for glycation risk
• Trained on high-throughput LC-MS/MS proteomics data

Advanced predictors incorporate 3D structural data from X-ray crystallography, cryo-EM, or predicted structures (e.g., AlphaFold2) to assess solvent accessibility and local flexibility. A residue matching a sequence motif may remain unmodified if buried in the hydrophobic core. Solvent Accessible Surface Area (SASA) calculations and B-factor analysis from crystallographic data quantify the structural exposure of potential modification sites. Molecular dynamics simulations further capture transient unfolding events that expose cryptic modification hotspots.

• Integrates PDB structures or AlphaFold2 predictions
• Calculates per-residue SASA values
• Uses B-factors as flexibility proxies
• Captures cryptic sites via MD sampling

Complementarity-determining regions (CDRs), particularly the CDR-H3 loop, are disproportionately susceptible to PTMs due to their high solvent exposure and conformational flexibility. Prediction platforms apply specialized scoring matrices that weight modifications in CDRs more heavily than framework regions. Aspartic acid isomerization in CDR loops can alter binding geometry, while N-terminal pyroglutamate formation can block antigen binding entirely. Tools like MOE and Schrödinger's BioLuminate provide residue-level risk heatmaps mapped onto antibody structures.

• CDR-H3 receives highest risk weighting
• Flags Asp isomerization in binding interfaces
• Detects N-terminal pyroglutamate formation risk
• Generates per-residue risk heatmaps

Leading platforms validate predictions against experimental forced degradation studies where antibodies are subjected to elevated temperature, pH extremes, and oxidative stress. Machine learning models are trained to correlate in silico risk scores with experimentally measured modification rates from peptide mapping and intact mass analysis. This closed-loop validation enables platforms to calibrate prediction thresholds, distinguishing between modifications that occur rapidly under stress versus those that remain stable over a 2-year shelf life at 4°C.

• Correlates predictions with 40°C stress studies
• Validates against peptide mapping data
• Calibrates thresholds for real-time stability
• Distinguishes acute vs. chronic degradation risk

PTM prediction is not performed in isolation but integrated into broader developability assessment workflows. Platforms combine modification risk with predictions for aggregation propensity (spatial aggregation propensity, SAP), viscosity, and hydrophobic interaction chromatography (HIC) retention time. This multi-parameter optimization identifies candidates where PTM liabilities coincide with poor biophysical properties, enabling early triage. Pareto-optimal ranking surfaces candidates that balance chemical stability with favorable manufacturability profiles.

• Combines PTM risk with aggregation prediction (SAP)
• Integrates viscosity and HIC retention forecasts
• Enables multi-parameter candidate ranking
• Identifies Pareto-optimal stability-manufacturability trade-offs

Beyond prediction, platforms suggest sequence mutations to eliminate PTM hotspots while preserving antigen binding. For deamidation-prone NG motifs, conservative substitutions (e.g., Asn→Gln or Gly→Ala) are proposed and evaluated for their impact on binding free energy (ΔΔG) using in silico mutagenesis. Generative models can propose complete CDR loop redesigns that maintain paratope electrostatics while eliminating all predicted chemical liabilities, accelerating the engineering of stable, manufacturable antibody therapeutics.

• Proposes conservative mutations (Asn→Gln, Gly→Ala)
• Evaluates mutational impact via ΔΔG prediction
• Uses generative models for liability-free CDR redesign
• Preserves paratope electrostatics and binding affinity